Literature DB >> 24710776

Progressive hepatic mitochondrial dysfunction in premanifest Huntington's disease.

Rainer Hoffmann1, Sven H Stüwe, Oliver Goetze, Matthias Banasch, Peter Klotz, Carsten Lukas, Martin Tegenthoff, Christian Beste, Michael Orth, Carsten Saft.   

Abstract

BACKGROUND: A subclinical, hepatic involvement in manifest and premanifest Huntington's disease (HD) was recently demonstrated by using the (1) (3) C-methionine breath test (MeBT). In this longitudinal pilot study, we investigated whether there is evidence for progressive hepatic mitochondrial dysfunction in premanifest HD.
METHODS: The MeBT was performed within a group of 25 well-characterized premanifest HD mutation carriers at baseline and in a 14.5-month follow-up.
RESULTS: The total group of mutation carriers (P = 0.033; Cohen's d = 0.6) and the subgroup of mutation carriers from our PreHD-B subgroup (nearer to disease onset; P = 0.030; Cohen's d = 1.12) revealed a lower amount of exhaled (13) CO2 in the follow-up.
CONCLUSIONS: This study demonstrates in vivo progressive, subclinical, hepatic involvement in premanifest HD. Limitations of the study, such as high variance in breath test results, are discussed.
© 2014 International Parkinson and Movement Disorder Society.

Entities:  

Keywords:  liver; methionine; mitochondria; premanifest Huntington's disease

Mesh:

Substances:

Year:  2014        PMID: 24710776     DOI: 10.1002/mds.25862

Source DB:  PubMed          Journal:  Mov Disord        ISSN: 0885-3185            Impact factor:   10.338


  11 in total

1.  Peripheral huntingtin silencing does not ameliorate central signs of disease in the B6.HttQ111/+ mouse model of Huntington's disease.

Authors:  Sydney R Coffey; Robert M Bragg; Shawn Minnig; Seth A Ament; Jeffrey P Cantle; Anne Glickenhaus; Daniel Shelnut; José M Carrillo; Dominic D Shuttleworth; Julie-Anne Rodier; Kimihiro Noguchi; C Frank Bennett; Nathan D Price; Holly B Kordasiewicz; Jeffrey B Carroll
Journal:  PLoS One       Date:  2017-04-28       Impact factor: 3.240

Review 2.  Metabolism in Huntington's disease: a major contributor to pathology.

Authors:  Akanksha Singh; Namita Agrawal
Journal:  Metab Brain Dis       Date:  2021-10-27       Impact factor: 3.655

Review 3.  Systemic manifestation and contribution of peripheral tissues to Huntington's disease pathogenesis.

Authors:  Chia-Lung Chuang; Fabio Demontis
Journal:  Ageing Res Rev       Date:  2021-05-09       Impact factor: 11.788

4.  HdhQ111 Mice Exhibit Tissue Specific Metabolite Profiles that Include Striatal Lipid Accumulation.

Authors:  Jeffrey B Carroll; Amy Deik; Elisa Fossale; Rory M Weston; Jolene R Guide; Jamshid Arjomand; Seung Kwak; Clary B Clish; Marcy E MacDonald
Journal:  PLoS One       Date:  2015-08-21       Impact factor: 3.240

5.  Metabolic disruption identified in the Huntington's disease transgenic sheep model.

Authors:  Renee R Handley; Suzanne J Reid; Stefano Patassini; Skye R Rudiger; Vladimir Obolonkin; Clive J McLaughlan; Jessie C Jacobsen; James F Gusella; Marcy E MacDonald; Henry J Waldvogel; C Simon Bawden; Richard L M Faull; Russell G Snell
Journal:  Sci Rep       Date:  2016-02-11       Impact factor: 4.379

6.  Longitudinal in vivo MRI in a Huntington's disease mouse model: Global atrophy in the absence of white matter microstructural damage.

Authors:  Jessica J Steventon; Rebecca C Trueman; Da Ma; Emma Yhnell; Zubeyde Bayram-Weston; Marc Modat; Jorge Cardoso; Sebastian Ourselin; Mark Lythgoe; Andrew Stewart; Anne E Rosser; Derek K Jones
Journal:  Sci Rep       Date:  2016-09-01       Impact factor: 4.379

7.  High-resolution respirometry of fine-needle muscle biopsies in pre-manifest Huntington's disease expansion mutation carriers shows normal mitochondrial respiratory function.

Authors:  Eva Buck; Martina Zügel; Uwe Schumann; Tamara Merz; Anja M Gumpp; Anke Witting; Jürgen M Steinacker; G Bernhard Landwehrmeyer; Patrick Weydt; Enrico Calzia; Katrin S Lindenberg
Journal:  PLoS One       Date:  2017-04-13       Impact factor: 3.240

8.  Effects of mutant huntingtin inactivation on Huntington disease-related behaviours in the BACHD mouse model.

Authors:  Rachel Y Cheong; Barbara Baldo; Muhammad U Sajjad; Deniz Kirik; Åsa Petersén
Journal:  Neuropathol Appl Neurobiol       Date:  2021-01-12       Impact factor: 8.090

9.  Patterns of CAG repeat instability in the central nervous system and periphery in Huntington's disease and in spinocerebellar ataxia type 1.

Authors:  Ricardo Mouro Pinto; Larissa Arning; James V Giordano; Pedram Razghandi; Marissa A Andrew; Tammy Gillis; Kevin Correia; Jayalakshmi S Mysore; Debora-M Grote Urtubey; Constanze R Parwez; Sarah M von Hein; H Brent Clark; Huu Phuc Nguyen; Eckart Förster; Allison Beller; Suman Jayadaev; C Dirk Keene; Thomas D Bird; Diane Lucente; Jean-Paul Vonsattel; Harry Orr; Carsten Saft; Elisabeth Petrasch-Parwez; Vanessa C Wheeler
Journal:  Hum Mol Genet       Date:  2020-08-29       Impact factor: 6.150

10.  Safety and Tolerability of SRX246, a Vasopressin 1a Antagonist, in Irritable Huntington's Disease Patients-A Randomized Phase 2 Clinical Trial.

Authors:  Michael J Brownstein; Neal G Simon; Jeffrey D Long; Jon Yankey; Hilda T Maibach; Merit Cudkowicz; Christopher Coffey; Robin A Conwit; Codrin Lungu; Karen E Anderson; Steven M Hersch; Dixie J Ecklund; Eve M Damiano; Debra E Itzkowitz; Shifang Lu; Marianne K Chase; Jeremy M Shefner; Andrew McGarry; Brenda Thornell; Catherine Gladden; Michele Costigan; Padraig O'Suilleabhain; Frederick J Marshall; Amy M Chesire; Paul Deritis; Jamie L Adams; Peter Hedera; Kelly Lowen; H Diana Rosas; Amie L Hiller; Joseph Quinn; Kellie Keith; Andrew P Duker; Christina Gruenwald; Angela Molloy; Cara Jacob; Stewart Factor; Elaine Sperin; Danny Bega; Zsazsa R Brown; Lauren C Seeberger; Victor W Sung; Melanie Benge; Sandra K Kostyk; Allison M Daley; Susan Perlman; Valerie Suski; Patricia Conlon; Matthew J Barrett; Stephanie Lowenhaupt; Mark Quigg; Joel S Perlmutter; Brenton A Wright; Elaine Most; Guy J Schwartz; Jessica Lamb; Rosalind S Chuang; Carlos Singer; Karen Marder; Joyce A Moran; John R Singleton; Meghan Zorn; Paola V Wall; Richard M Dubinsky; Carolyn Gray; Carolyn Drazinic
Journal:  J Clin Med       Date:  2020-11-16       Impact factor: 4.241

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.